High prevalence of epigenetic inactivation of the human four and a half LIM domains 1 gene in human oral cancer

Koike,Kazuyuki; Kasamatsu,Atsushi; Iyoda,Manabu; Saito,Yasuhiro; Kouzu,Yukinao; Koike,Hirofumi; Sakamoto,Yosuke; Ogawara,Katsunori; Tanzawa,Hideki; Uzawa,Katsuhiro

doi:10.3892/ijo.2012.1677

High prevalence of epigenetic inactivation of the human four and a half LIM domains 1 gene in human oral cancer

Authors:
- Kazuyuki Koike
- Atsushi Kasamatsu
- Manabu Iyoda
- Yasuhiro Saito
- Yukinao Kouzu
- Hirofumi Koike
- Yosuke Sakamoto
- Katsunori Ogawara
- Hideki Tanzawa
- Katsuhiro Uzawa
View Affiliations

Affiliations: Department of Clinical Molecular Biology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba 260-8670, Japan, Department of Dentistry and Oral-Maxillofacial Surgery, Chiba University Hospital, Chuo-ku, Chiba 260-8670, Japan
Published online on: October 24, 2012 https://doi.org/10.3892/ijo.2012.1677
Pages: 141-150

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The four and a half LIM domains 1 (FHL1) gene has been related to carcinogenesis. However, the expression status of FHL1 in human oral squamous cell carcinoma (OSCC) remains unclear and the detailed mechanism of gene silencing is poorly understood. The aim of this study was to examine the FHL1 expression level and its regulatory mechanism in OSCCs. Quantitative reverse-transcriptase-polymerase chain reaction (PCR) and western blotting showed significant downregulation of FHL1 in all OSCC-derived cell lines (Sa3, HSC-2, HSC-3, HSC-4, HO-1-u-1, HO-1-N-1, KON and Ca9-22) compared to human normal oral keratinocytes. We also found that FHL1 mRNA expression was frequently downregulated (P<0.01) in 51 (86.4%) of 59 primary OSCCs compared with the corresponding normal oral tissues, while there was no significant difference between the status of the FHL1 protein expression in OSCCs and the clinicopathological features. Using methylation-specific PCR, we detected methylated FHL1 in all cell lines and treatment with the DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine restored the FHL1 expression. However, no significant restoration of FHL1 expression was observed using sodium butyrate, an inhibitor of histone deacetylase and chromatin immunoprecipitation showed that histone H3 lysine 9 in the FHL1 promoter region was significantly acetylated. In addition, no mutation in the entire coding region of the FHL1 gene was found. Therefore, our data suggested that inactivation of the FHL1 gene is a frequent event during oral carcinogenesis and that the mechanism of FHL1 downregulation in OSCCs is through DNA methylation of the promoter region rather than histone deacetylation or mutation.

View Figures

View References

1.	Lippman SM, Sudbø J and Hong WK: Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol. 23:346–356. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
3.	Bettendorf O, Piffkò J and Bànkfalvi A: Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol. 40:110–119. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Kademani D: Oral cancer. Mayo Clin Proc. 82:878–887. 2007. View Article : Google Scholar
5.	Tatsumoto T, Xie X, Blumenthal R, Okamoto I and Miki T: Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis. J Cell Biol. 147:921–928. 1999. View Article : Google Scholar : PubMed/NCBI
6.	Shinozuka K, Uzawa K, Fushimi K, et al: Downregulation of carcinoembryonic antigen-related cell adhesion molecule 1 in oral squamous cell carcinoma: correlation with tumor progression and poor prognosis. Oncology. 76:387–397. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Brown S, McGrath MJ, Ooms LM, Gurung R, Maimone MM and Mitchell CA: Characterization of two isoforms of the skeletal muscle LIM protein 1, SLIM1. Localization of SLIM1 at focal adhesions and the isoform slimmer in the nucleus of myoblasts and cytoplasm of myotubes suggests distinct roles in the cytoskeleton and in nuclear-cytoplasmic communication. J Biol Chem. 274:27083–27091. 1999.
8.	McGrath MJ, Mitchell CA, Coghill ID, Robinson PA and Brown S: Skeletal muscle LIM protein 1 (SLIM1/FHL1) induces alpha 5 beta 1-integrin-dependent myocyte elongation. Am J Physiol Cell Physiol. 285:C1513–C1526. 2003. View Article : Google Scholar : PubMed/NCBI
9.	Loughna PT, Mason P, Bayol S and Brownson C: The LIM-domain protein FHL1 (SLIM 1) exhibits functional regulation in skeletal muscle. Mol Cell Biol Res Commun. 3:136–140. 2000. View Article : Google Scholar : PubMed/NCBI
10.	Chen DH, Raskind WH, Parson WW, et al: A novel mutation in FHL1 in a family with X-linked scapuloperoneal myopathy: phenotypic spectrum and structural study of FHL1 mutations. J Neurol Sci. 296:22–29. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Oku N, Sasabe E, Ueta E, Yamamoto T and Osaki T: Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res. 66:5251–5257. 2006. View Article : Google Scholar
12.	Sakashita K, Mimori K, Tanaka F, et al: Clinical significance of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol. 15:2293–2300. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Fackler MJ, McVeigh M, Mehrotra J, et al: Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res. 64:4442–4452. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Fuks F: DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev. 15:490–495. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Hassig CA and Schreiber SL: Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol. 1:300–308. 1997. View Article : Google Scholar : PubMed/NCBI
16.	Huang L: Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol. 209:611–616. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Endo Y, Uzawa K, Mochida Y, et al: Sarcoendoplasmic reticulum Ca(2+) ATPase type 2 downregulated in human oral squamous cell carcinoma. Int J Cancer. 110:225–231. 2004.
18.	Shimada K, Uzawa K, Kato M, et al: Aberrant expression of RAB1A in human tongue cancer. Br J Cancer. 92:1915–1921. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Saito K, Uzawa K, Endo Y, et al: Plasma membrane Ca²⁺ ATPase isoform 1 down-regulated in human oral cancer. Oncol Rep. 15:49–55. 2006.
20.	Kasamatsu A, Uzawa K, Nakashima D, et al: Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int J Mol Med. 16:269–273. 2005.PubMed/NCBI
21.	Sakuma K, Kasamatsu A, Yamatoji M, et al: Expression status of Zic family member 2 as a prognostic marker for oral squamous cell carcinoma. J Cancer Res Clin Oncol. 136:553–559. 2010. View Article : Google Scholar : PubMed/NCBI
22.	Tanaka C, Uzawa K, Shibahara T, Yokoe H, Noma H and Tanzawa H: Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J Dent Res. 82:607–611. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Kouzu Y, Uzawa K, Kato M, et al: WISP-2 expression in human salivary gland tumors. Int J Mol Med. 17:567–573. 2006.PubMed/NCBI
24.	Onda T, Uzawa K, Endo Y, et al: Ubiquitous mitochondrial creatine kinase downregulated in oral squamous cell carcinoma. Br J Cancer. 94:698–709. 2006.PubMed/NCBI
25.	Sakuma T, Uzawa K, Onda T, et al: Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol. 29:117–124. 2006.PubMed/NCBI
26.	Kato Y, Uzawa K, Yamamoto N, et al: Overexpression of Septin1: possible contribution to the development of oral cancer. Int J Oncol. 31:1021–1028. 2007.PubMed/NCBI
27.	Nomura H, Uzawa K, Yamano Y, et al: Overexpression and altered subcellular localization of autophagy-related 16-like 1 in human oral squamous-cell carcinoma: correlation with lymphovascular invasion and lymph-node metastasis. Hum Pathol. 40:83–91. 2009. View Article : Google Scholar
28.	Iyoda M, Kasamatsu A, Ishigami T, et al: Epithelial cell transforming sequence 2 in human oral cancer. PloS One. 5:e140822010. View Article : Google Scholar : PubMed/NCBI
29.	Yamatoji M, Kasamatsu A, Kouzu Y, et al: Dermatopontin: a potential predictor for metastasis of human oral cancer. Int J Cancer. 130:2903–2911. 2012. View Article : Google Scholar : PubMed/NCBI
30.	Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW and Barrett JC: Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res. 59:5724–5731. 1999.PubMed/NCBI
31.	Verburg FA, Wäschle K, Reiners C, Giovanella L and Lentjes EG: Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients. Horm Metab Res. 42:736–739. 2010. View Article : Google Scholar : PubMed/NCBI
32.	Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002. View Article : Google Scholar : PubMed/NCBI
33.	Van der Auwera I, Van Laere SJ, Van den Bosch SM, et al: Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer. 99:1735–1742. 2008.PubMed/NCBI
34.	Kimura H, Hayashi-Takanaka Y, Goto Y, Takizawa N and Nozaki N: The organization of histone H3 modifications as revealed by a of specific monoclonal antibodies. Cell Struct Funct. 33:61–73. 2008. View Article : Google Scholar : PubMed/NCBI
35.	Wang LL, Qiu GR, Fu WN, Yuan ZW and Sun KL: Transcriptional regulation of Fhl1 by estradiol in rat myoblastocytes. Steroids. 75:368–372. 2010. View Article : Google Scholar : PubMed/NCBI
36.	Shen Y, Jia Z, Nagele RG, Ichikawa H and Goldberg GS: SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Res. 66:1543–1552. 2006. View Article : Google Scholar : PubMed/NCBI
37.	Fryknas M, Wickenberg-Bolin U, Goransson H, et al: Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol. 27:211–220. 2006. View Article : Google Scholar : PubMed/NCBI
38.	Li X, Jia Z, Shen Y, et al: Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci. 99:1326–1333. 2008. View Article : Google Scholar : PubMed/NCBI
39.	Yuan J, Luo RZ, Fujii S, et al: Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res. 63:4174–4180. 2003.PubMed/NCBI
40.	Chen K, Sawhney R, Khan M, et al: Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 133:1131–1138. 2007. View Article : Google Scholar : PubMed/NCBI
41.	Henken FE, Wilting SM, Overmeer RM, et al: Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer. 97:1457–1464. 2007. View Article : Google Scholar : PubMed/NCBI
42.	Magdinier F and Wolffe AP: Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA. 98:4990–4995. 2001. View Article : Google Scholar : PubMed/NCBI
43.	Cheung P and Lau P: Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol. 19:563–573. 2005. View Article : Google Scholar : PubMed/NCBI
44.	Hong S, Derfoul A, Pereira-Mouries L and Hall DJ: A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes. FASEB J. 23:3539–3552. 2009. View Article : Google Scholar : PubMed/NCBI